221 related articles for article (PubMed ID: 34248851)
1. Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma
Zhang Z; Reiding KR; Wu J; Li Z; Xu X
Front Endocrinol (Lausanne); 2021; 12():692910. PubMed ID: 34248851
[TBL] [Abstract][Full Text] [Related]
2. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide, carnitine, choline and betaine.
Shi L; Guo M; Shi C; Gao G; Xu X; Zhang C; Fu J; Ni Y; Wang F; Xue X; Yu F
J Cancer Res Clin Oncol; 2024 Mar; 150(3):142. PubMed ID: 38503944
[TBL] [Abstract][Full Text] [Related]
4. Serum Linkage-Specific Sialylation Changes Are Potential Biomarkers for Monitoring and Predicting the Recurrence of Papillary Thyroid Cancer Following Thyroidectomy.
Cao Z; Zhang Z; Liu R; Wu M; Li Z; Xu X; Liu Z
Front Endocrinol (Lausanne); 2022; 13():858325. PubMed ID: 35574008
[TBL] [Abstract][Full Text] [Related]
5. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
6. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS.
Liu S; Cheng L; Fu Y; Liu BF; Liu X
J Proteomics; 2018 Jun; 181():225-237. PubMed ID: 29698801
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
8. Nomograms Based on Serum
Zhang Z; Cao Z; Liu R; Li Z; Wu J; Liu X; Wu M; Xu X; Liu Z
Curr Oncol; 2022 Aug; 29(9):6018-6034. PubMed ID: 36135043
[TBL] [Abstract][Full Text] [Related]
9. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
10. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Potential of Plasma IgG N-glycans in Discriminating Thyroid Cancer from Benign Thyroid Nodules and Healthy Controls.
Zhang Z; Wu J; Liu P; Kang L; Xu X
Front Oncol; 2021; 11():658223. PubMed ID: 34476207
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
14. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases.
Clerc F; Novokmet M; Dotz V; Reiding KR; de Haan N; Kammeijer GSM; Dalebout H; Bladergroen MR; Vukovic F; Rapp E; ; Targan SR; Barron G; Manetti N; Latiano A; McGovern DPB; Annese V; Lauc G; Wuhrer M
Gastroenterology; 2018 Sep; 155(3):829-843. PubMed ID: 29792883
[TBL] [Abstract][Full Text] [Related]
15. The Role of Vitamin D, Platelet-Derived Growth Factor and Insulin-Like Growth Factor 1 in the Progression of Thyroid Diseases.
Abdellateif MS; Shaarawy S; Elesawy YF; Mansour M; Tharwat E; Ibrahim NH; Eissa MS
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2083-2089. PubMed ID: 32711436
[TBL] [Abstract][Full Text] [Related]
16. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
17. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
[No Abstract] [Full Text] [Related]
18. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
19. Plasma N-Glycome Signature of Down Syndrome.
Borelli V; Vanhooren V; Lonardi E; Reiding KR; Capri M; Libert C; Garagnani P; Salvioli S; Franceschi C; Wuhrer M
J Proteome Res; 2015 Oct; 14(10):4232-45. PubMed ID: 26334954
[TBL] [Abstract][Full Text] [Related]
20. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
